Skip to content

Climb Bio, Inc. CLYM Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Amgen logo
AmgenAMGN
Vera Therapeutics logo
Vera TherapeuticsVERA
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s software and technology licenses, net?
Climb Bio, Inc. (CLYM) reported software and technology licenses, net of $1.53M in Q1 2026.
How has Climb Bio, Inc.'s software and technology licenses, net changed year-over-year?
Climb Bio, Inc.'s software and technology licenses, net increased by 577.0% year-over-year, from $226K to $1.53M.
What is the long-term trend for Climb Bio, Inc.'s software and technology licenses, net?
Over 5 years (2020 to 2025), Climb Bio, Inc.'s software and technology licenses, net has grown at a -10.3% compound annual growth rate (CAGR), from $2.63M to $1.53M.